---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-111027"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:41:45.714692+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Apogee reports positive Phase 1 APG777 data: half-life ~75 days, sustained PD effect up to 9 months

## Summary
- APG777 half-life of ~75 days is about 3–5× longer than currently approved moderate-to-severe AD treatments.
- Near-complete pSTAT6 inhibition and sustained TARC suppression observed up to 9 months after a single dose.
- No serious adverse events; treatment-emergent AEs were mild-to-moderate and unrelated to study drug.
- Phase 2 proof-of-concept data in moderate-to-severe AD expected in 2H 2025.
- Company plans R&D Day on December 2, 2024 to update on APG777 and pipeline.

## SEC filing metadata
- accession: 0001104659-24-111027
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465924111027/0001104659-24-111027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465924111027/tm2426705d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-111027
- JSON: https://secwatch.observer/filing/0001104659-24-111027.json
- Plain text: https://secwatch.observer/filing/0001104659-24-111027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.